2016 Archived Content

High-Content Analysis Link Phenotypic Screening Link

CHI’s Thirteenth Annual High-Content Analysis meeting, the premier event showcasing the latest advancements in HCA applications and technologies, returns to San Diego with a new program. Over the years we have observed the technology mature and its adoption spread into many areas of compound screening/evaluation and functional analysis. The High-Content Analysis meeting will focus on the next steps of technology development, including screening of 3D and physiologically relevant complex models, ultra-high resolution and high-throughput imaging, more advanced image analysis and data management, and new assays and applications. The co-located Second Annual Phenotypic Screening meeting will address the advantages of phenotypic screening vs. target-based screening, and focus on assay development, selection of physiologically relevant models and subsequent target identification, as well as case studies of phenotypic screens from leading pharma. Join the original High-Content Analysis event and get access to two tracks featuring a cutting-edge scientific agenda, expanded exhibit hall and technology showcases, and an offering of user group meetings and dinner courses.

Featured Speakers:

Paul AndrewsPaul Andrews
Director, National Phenotypic Screening
University of Dundee


Anthony M. DaviesAnthony M. Davies
Director, Translational Cell Imaging
Queensland University of Technology


Erik HettErik Hett
Team Leader, Chemical & Molecular Therapeutics


Susanne Heynen-GenelSusanne Heynen-Genel
Director, High-Content Screening
Sanford Burnham Prebys Medical Discovery Institute


Zhuyin LiZhuyin Li
Team Lead, Lead Discovery & Optimization
Bristol-Myers Squibb


Ulrich SchopferUlrich Schopfer
Head, Integrated Lead Discovery


D. Lansing TaylorD. Lansing Taylor
University of Pittsburgh Drug Discovery Institute


Alan WaggonerAlan Waggoner
Director, Molecular Biosensor and Imaging Center
Carnegie Mellon University


Wei ZhengWei Zheng
Group Leader, Preclinical Innovation


Coverage Includes:

  • Case studies in phenotypic drug discovery
  • High-content and phenotypic screening of 3D cell culture 
  • Novel models for screening, including organoids, organotypic primary cells, iPSCs and spheroids
  • Assay development and case studies in HCA
  • Target/pathway identification and validation
  • Data analysis for phenotypic and high-content screening
  • Chemical genomics and chemical proteomics
  • Quantitative systems pharmacology
  • Live-cell imaging
  • Ultra-high resolution imaging

Dinner Courses:

Wednesday, February 10, 6:00-9:00 pm

Introduction to High-Content Phenotypic Screening - View Details

Instructor: Anthony M. Davies, Ph.D., Center Director, Translational Cell Imaging Queensland (TCIQ), Institute of Health Biomedical Innovation, Queensland University of Technology

Thursday, February 11, 6:30-9:00 pm

Expert ThinkTank: How to Meet the Need for Physiologically Relevant Assays - View Details

Moderator: Lisa Minor, Ph.D., President, In Vitro Strategies, LLC

Sponsor & Exhibit Information:

2016 ProspectusView 2016 Prospectus
Reserve your space early!